Sanofi says no major restructuring despite upcoming Dupixent patent expiration

Sanofi's new chief executive, Belén Garijo, said after six months in charge that the company will not embark on a major overhaul of its business or research pipeline.

The comment was made as the biologic Dupixent, a major revenue source for the French drugmaker, nears a patent cliff that could significantly cut its earnings.

Sanofi plans to rely on its existing product lineup and ongoing development projects rather than pursuing large‑scale restructuring.

Analysts note that while the firm hopes its diversified portfolio will soften the impact, the absence of a sweeping plan may leave it exposed to competitive pressures.